Drug discovery services in the UK continue to attract acquirers

Rachel Cresswell 12 February 2018


According to Catalyst Corporate Finance, UK service-based pharmaceutical businesses involved in the "smart" parts of the market are experiencing mounting interest from both UK and foreign acquirers despite Brexit and other macro concerns. 

In January 2018 alone, three drug discovery businesses have been acquired, most recently with Spectris buying Manchester-based Concept Life Sciences in order to expand its testing services and capitalise on growth opportunities in the pharmaceutical and life sciences sectors.  This deal follows Charles River's acquisition of UK-based KWS Biotest and Eurofins' acquisition of UK CRO Selcia.

These acquisitions continue a trend of increasing deal activity in drug discovery services and related businesses, which began last year when Phoenix Private Equity acquired Sygnature Discovery.   Fifteen UK drug discovery service and related businesses have been acquired or raised capital during 2016 and 2017, and this upward trend looks set to continue in 2018. 

Catalyst’s Tom Cowap, a Principal in the healthcare sector team, identifies some of the drivers behind this trend: “Outsourcing is now a well-documented trend for Big Pharma on account of historically profitable drugs coming out of marketing exclusivity, the lower returns on investment in new drugs and the stricter regulatory requirements, which in turn lead to higher failure rates, making it harder to get molecules to market."

Two less publicised shifts have also occurred: “In search of financial returns, Big Pharma has started to move into new areas that it would not have previously tackled, such as rare diseases. This means that Big Pharma companies are operating in areas where they may not have in-house expertise, driving them to look for that expertise externally - including in the preclinical stage. Big Pharma also reduced its level of investment in its early stage pipeline some 7 years ago to focus on developing and launching molecules in its clinical stage pipeline; and as a result of this, it later had very little in its pipeline which has motivated it to acquire drug candidates through smaller businesses."

“External investors have taken note of Big Pharma’s appetite for development businesses, which has in turn attracted early stage investors into the market and increased the availability of funding.  This has also attracted more talent to the market – creating a virtuous circle. These smaller start-ups are generally funded by specialist venture capital funds and we believe that this will continue for the short term at least.  The market fundamentals and recent acquisitions show that there are returns to be made, and as long as that remains the case, investors will put money into the market."  




Make a comment

To voice your opinion, please Log in or Register.

Pf Magazine

Your resource for news, features, interviews, careers and events in the pharma industry.

Click here for the latest issue and to subscribe.